Business Context and Reporting Period
This Form 8-K is a current report filed by Histogenics Corporation (not Ocugen, Inc.) on September 29, 2016. The filing details the closing of a private placement of equity securities and the creation of a new class of convertible preferred stock.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels. Instead, it reports the following capital raise details:
- Common Stock Issued: 2,596,059 shares at $2.25 per share.
- Series A Convertible Preferred Stock Issued: 24,158.8693 shares with a stated value of $1,000 per share, convertible into approximately 10,737,275 common shares.
- Warrants Issued: Warrants to purchase up to 13,333,334 common shares at an exercise price of $2.25 per share.
- Placement Agent Warrant: 133,333 shares issued to H.C. Wainwright & Co., LLC at $2.25 per share.
- Use of Proceeds: Net proceeds are designated for working capital and general corporate purposes.
Material Changes and Corporate Actions
The primary material change is the entry into a Material Definitive Agreement and the unregistered sale of equity securities. Key structural changes include:
- Capital Structure: Introduction of Series A Convertible Preferred Stock with specific conversion limits (capped at 4.99% beneficial ownership unless adjusted to 9.99% with notice).
- Stockholder Approval: The conversion feature of the Series A Preferred Stock and the exercise of warrants are contingent upon stockholder approval. Until approved, the preferred shares are not convertible.
- Support Agreements: Stockholders holding approximately 45.8% of outstanding common stock entered into agreements to vote in favor of the transaction proposals.
- Lock-up: The company is restricted from issuing additional common stock or equivalents for 90 days following the effective date of the registration statement.
Guidance, Risks, and Contingencies
The filing outlines several contingencies and risks associated with the transaction:
- Registration Risk: The securities were issued under Section 4(a)(2) and Regulation D exemptions. The company must file a registration statement within 30 days and have it declared effective within 75 days (or 110 days if reviewed).
- Conversion Contingency: If stockholders do not approve the conversion feature, the Series A Preferred Stock will remain non-convertible.
- Warrant Exercise: Warrants include a cashless-exercise feature if no effective registration statement is available six months post-closing.
- Liquidation Preference: In the event of dissolution, proceeds are distributed pari passu between common and Series A holders on an as-if-converted basis.
Investor Verification Checklist
- Verify the outcome of the stockholder vote required to approve the conversion of Series A Preferred Stock and the exercise of warrants.
- Confirm the filing and effective date of the registration statement for the resale of the issued securities.
- Review the full Certificate of Designation (Exhibit 3.3) for detailed rights and limitations of the Series A Preferred Stock.
- Monitor the company's cash position to ensure the raised capital is sufficient for stated working capital needs.
- Check for any subsequent filings regarding the 90-day lock-up period on new equity issuances.